Stockscreener 앱 받기
1.50
0.66%
-0.01
시간 외 거래:
1.49
-0.01
-0.67%
전일 마감가:
$1.51
열려 있는:
$1.49
하루 거래량:
2.71M
Relative Volume:
0.77
시가총액:
$1.12B
수익:
$581.12M
순이익/손실:
$-212.92M
주가수익비율:
-5.4785
EPS:
-0.2738
순현금흐름:
$-174.22M
1주 성능:
+2.74%
1개월 성능:
+20.97%
6개월 성능:
+25.00%
1년 성능:
+5.63%
1일 변동 폭
$1.49
$1.53
1주일 범위
$1.455
$1.53
52주 변동 폭
$0.9769
$1.73
Opko Health Inc Stock (OPK) Company Profile
명칭
Opko Health Inc
전화
305-575-4181
주소
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK vs TMO, DHR, NTRA, A, IQV
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.50 | 1.09B | 581.12M | -212.92M | -174.22M | -0.2738 |
TMO
Thermo Fisher Scientific Inc
|
630.70 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.68 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
338.70 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
157.69 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.38 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-20 | 개시 | JP Morgan | Neutral |
| 2025-10-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-04-25 | 개시 | JP Morgan | Neutral |
| 2023-06-29 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-01-24 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | 개시 | Ladenburg Thalmann | Buy |
| 2019-11-25 | 개시 | Piper Jaffray | Overweight |
| 2018-03-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-06-21 | 재확인 | Standpoint Research | Buy |
| 2016-06-03 | 개시 | Standpoint Research | Buy |
| 2016-03-31 | 재확인 | Barrington Research | Outperform |
| 2015-10-16 | 개시 | JP Morgan | Overweight |
| 2015-09-11 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-03-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2014-05-12 | 재확인 | Oppenheimer | Outperform |
| 2014-03-14 | 개시 | Oppenheimer | Outperform |
| 2013-11-13 | 재확인 | Ladenburg Thalmann | Buy |
| 2013-05-30 | 재확인 | Ladenburg Thalmann | Buy |
| 2012-10-22 | 개시 | Barrington Research | Outperform |
| 2011-12-01 | 재확인 | Ladenburg Thalmann | Buy |
| 2011-07-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Opko Health Inc 주식(OPK)의 최신 뉴스
COCP: 5 Million Private Placement with OPKO Health - Smartkarma
Is OPK Worth Buying as Valuation Meets Improving Business Trends? - Zacks Investment Research
OPK Raises $125 Million Against Royalties: What Investors Should Know - Yahoo Finance
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going? - TradingView
Zacks Research Has Positive View of OPKO Health Q3 Earnings - MarketBeat
OPKO (OPK) Latest Results Brief: EPS Prints Above Forecast in the Latest Reading; Shares After the Report: The Market Reaction Is MutedTrough Earnings Signal - Vinanet
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties - Yahoo Finance
Should OPKO Health’s Royalty-Backed US$125 Million Financing Shift Matter to OPKO Health (OPK) Investors? - Sahm
OPKO Health (OPK) Retreats to $1.38 as Support at $1.31 Comes into FocusMomentum Surge Alerts - vinanet.vn
OPKO Health (OPK) Raises $125 Million, Is The Upside Already Priced In? - Sahm
OPKO Health Raises $125 Million in Senior Secured Debt Financing - Minichart
OPKO Health (OPK) Slips to $1.38, Pressing Key Support at $1.31ATR Trailing Stop - Vinanet
OPKO Health Raises $125M Through Senior Secured Notes Backed by Mazdutide Royalties - Kalkine Media
OPKO Health Raises $125 Million in Additional Royalty-Backed Notes Under Amended HCR Agreement - TradingView
OPKO Health (NASDAQ:OPK) Trading Down 5.4%Here's What Happened - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Rating of "Hold" by Analysts - MarketBeat
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests - OPKO Health, Inc.
OPKO Health, Inc. Expands Strategic Relationship with Healthcare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests - marketscreener.com
OPKO Health secures $125m financing backed by mazdutide royalties - Investing.com Nigeria
OPKO Health Issues Additional $125 Million in Senior Notes Secured by Mazdutide Royalties - marketscreener.com
OPKO Health raises $125M in notes backed by mazdutide royalties - StreetInsider
OPKO Issues $125M Notes While Keeping Future Mazdutide Royalties - Stock Titan
OPKO Health, Inc. announced that it has received $375 million in funding from Healthcare Royalty Management, LLC - marketscreener.com
Opko Health, Inc. (OPK) Stock Analysis: Exploring A 214.75% Potential Upside - DirectorsTalk Interviews
Does OPKO Health’s Sharply Narrowed Q2 Loss Reset the Bull Case for OPKO Health (OPK)? - Sahm
OPKO Health (OPK) Advances 1.46% to $1.39, Approaching Key Resistance at $1.46Ichimoku Kumo Twist - Vinanet
OPKO Health Inc (OPK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Opko Health | SCHEDULE 13D: Others - Moomoo
OPKO Health, Inc. Discloses Investment in Cocrystal Pharma with 29.6% Stake - TradingView
OPKO Health: Mazdutide And MDX-2201 Could Change Everything (NASDAQ:OPK) - Seeking Alpha
OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
OPKO Health invests $5 million in Cocrystal Pharma By Investing.com - Investing.com South Africa
Weekly Recap: Q2 2026 financial results and MDX trial timelines - TradingView
Cocrystal Pharma Raises $5 Million in Private Placement With OPKO Health at $0.9134/Share - TradingView
Cocrystal Pharma (NASDAQ: COCP) secures $5M investment from OPKO Health - Stock Titan
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health - GlobeNewswire
Opko Health Earnings Call Highlights Pipeline, Profit Pivot - The Globe and Mail
Opko Health Launches Early MASH Trial That Could Shape Its Next Growth Chapter - The Globe and Mail
OPKO Health: A Hold As Progress Continues (NASDAQ:OPK) - Seeking Alpha
Opko Health, Inc. Revenue Breakdown – NASDAQ:OPK - TradingView
OPKO Health (OPK) Is Up 14.1% After Narrower Q2 Loss and New 2026 Revenue Guidance – Has The Bull Case Changed? - simplywall.st
Earnings Beat: OPKO Health, Inc. (NASDAQ:OPK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - news.futunn.com
OPKO Health FY2026 EPS Estimate Increased by HC Wainwright - MarketBeat
OPKO Health Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR) - The Globe and Mail
OPKO Health (NASDAQ:OPK) Reaches New 52-Week HighHere's Why - MarketBeat
Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results - Benzinga
OPKO Health (NASDAQ:OPK) Shares Gap Up Following Strong Earnings - MarketBeat
Why Is OPKO Health (NASDAQ:OPK) Stock Drawing Fresh Market Interest Today? - Kalkine Media
Piper Sandler Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $3 - Moomoo
OPK Looks 19.0% Overvalued on GF Value™ - GuruFocus
Opko Health Inc (OPK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Opko Health Inc 주식 (OPK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 21 '25 |
Buy |
1.33 |
580,000 |
768,807 |
216,706,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 20 '25 |
Buy |
1.33 |
580,000 |
771,328 |
216,126,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 19 '25 |
Buy |
1.31 |
580,000 |
759,115 |
215,546,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 18 '25 |
Buy |
1.27 |
533,300 |
678,906 |
214,966,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Oct 31 '25 |
Buy |
1.42 |
150,000 |
213,435 |
214,386,448 |
0.24%
1.51%
자본화:
|
볼륨(24시간):